Previous 10 | Next 10 |
VANCOUVER , Nov. 26, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treat...
Sierra Oncology (NASDAQ: SRRA ) has launched the MOMENTUM clinical trial for patients with myelofibrosis. More news on: Sierra Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...
- MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen - - Targeting enrollment of 180 symptomatic and anemic patients previously treated with a JAK inhibitor – - Top-line data anticipated i...
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference Canada NewsWire VANCOUVER, Nov. 14, 2019 - "Building Momentum for Patients with Myelofibrosis" scheduled for 6:00 p.m. GMT on November 20, 2019 - VANCOUVER , Nov. 14, 2019 /CNW/ - Sierra O...
Nano cap Sierra Oncology ( SRRA -19.4% ) slumps on a 4x surge in volume in reaction to the pricing of its public offering of convertible preferred stock and warrants. More news on: Sierra Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib Canada NewsWire VANCOUVER, Nov. 7, 2019 - Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra - - Amendments become effective upon Sierra On...
Sierra Oncology (NASDAQ: SRRA ): Q3 GAAP EPS of -$0.17 beats by $0.04 . More news on: Sierra Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- MOMENTUM Phase 3 myelofibrosis clinical trial anticipated to launch in Q4 2019 - VANCOUVER , Nov. 4, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet ...
Sierra Oncology (NASDAQ: SRRA ): Q2 GAAP EPS of -$0.20 in-line. More news on: Sierra Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Sierra preparing to launch the MOMENTUM Phase 3 myelofibrosis clinical trial expected in Q4 2019 - - Exploring non-dilutive options to support future continued development of DDR portfolio - VANCOUVER , Aug 8, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug develop...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...